Laserfiche WebLink
DocuSign Envelope ID: 040056EC-0D41-4D98-9C65-E01AE876A6AB <br /> EXHIBIT A <br /> List of Opioid Remediation Uses <br /> Settlement fund recipients shall choose from among abatement strategies, including but not <br /> limited to those listed in this Exhibit. The programs and strategies listed in this Exhibit are not <br /> exclusive, and fund recipients shall have flexibility to modify their abatement approach as <br /> needed and as new uses are discovered. <br /> PART ONE: TREATMENT <br /> A. TREAT OPIOID USE DISORDER (OUD) <br /> Support treatment of Opioid Use Disorder ("OUD") and any co-occurring Substance <br /> Use Disorder or Mental Health ("SUD/MH") conditions through evidence-based or <br /> evidence- informed programs' or strategies that may include, but are not limited to, those <br /> that:6 <br /> 1. Expand availability of treatment for OUD and any co-occurring SUD/MH <br /> conditions, including all forms of Medication for Opioid Use Disorder <br /> ("MOUD")7 approved by the U.S. Food and Drug Administration, including by <br /> making capital expenditures to purchase, rehabilitate, or expand facilities that <br /> offer treatment. <br /> 2. Support and reimburse evidence-based services that adhere to the American <br /> Society of Addiction Medicine ("ASAM") continuum of care for OUD and any <br /> co- occurring SUD/MH conditions. <br /> 3. Expand telehealth to increase access to treatment for OUD and any co-occurring <br /> SUD/MH conditions, including MOUD, as well as counseling, psychiatric <br /> support, and other treatment and recovery support services. <br /> ' Use of the terms "evidence-based," "evidence-informed," or "best practices" shall not limit the <br /> ability of recipients to fund innovative services or those built on culturally specific needs. <br /> Rather, recipients are encouraged to support culturally appropriate services and programs for <br /> persons with OUD and any co-occurring SUD/MH conditions. <br /> 6 As used in this Exhibit, words like "expand," "fund," "provide" or the like shall not indicate a <br /> preference for new or existing programs. <br /> Historically, pharmacological treatment for opioid use disorder was referred to as "Medication- <br /> Assisted Treatment" ("MAT"). It has recently been determined that the better term is <br /> "Medication for Opioid Use Disorder" ("MOUD"). This Exhibit will use "MOUD" going <br /> forward. Use of the term MOUD is not intended to and shall in no way limit abatement <br /> programs or strategies now or into the future as new strategies and terminology evolve. <br /> 1 <br />